NEOVII to Develop a Novel Vaccine for COVID-19 in an Exclusive Partnership With Tel Aviv University – WFMZ Allentown

May 12, 2020 medical

RAPPERSWIL, Switzerland, May 12, 2020 /PRNewswire/ -- Neovii, the Swiss-based biopharmaceutical company and a member of Israeli-based Neopharm Group, has signed a research and license agreement with Tel Aviv University's (TAU) RAMOT, its technology transfer company, to work in collaboration with a team led byProfessor Jonathan Gershoni of the School of Molecular Cell Biology and Biotechnologyto develop a novel and potentially life-saving COVID-19 vaccine.

The agreement will grant Neovii the exclusive right to develop and commercialize a novel and recently patented platform technology that has been developed by Professor Gershoni for the rapid discovery of epitope-based vaccines. The collaboration is focused on the development of a first-in-class COVID-19 vaccine that targets the Achilles' heel of the virus by reconstructing the coronavirus's Receptor Binding Motif (RBM), a critical structure of its "spike" protein.The "spike" protein itself is the major surface protein that the virus uses to bind to the cellular receptor that acts as the doorway into the human cell. After the spike protein binds to the human cell receptor, the viral membrane fuses with the human cell membrane, allowing the genome of the virus to enter human cells and begin infection.

"We have been working on coronaviruses for the last 15 yearsdeveloping a method of reconstructing and reconstituting the RBM structure of the spike protein in SARS-CoV and subsequently in MERS-CoV," explains Professor Gershoni. "The moment the genome of the new virus was published in early January 2020, we began the process of reconstituting the RBM of SARS-CoV-2, the virus that causes COVID-19, and expect to have a reconstituted RBM of the new virus soon.This is the basis for the new vaccine, which could be ready for use within a year to a year and a half."

"The smaller the target and the focus of the attack, the safer and greater the effectiveness of the vaccine," adds Prof. Gershoni."The virus takes far-reaching measures to hide its RBM from the human immune system, but the best way to 'win the war' is to develop a vaccine that specifically targets the virus's RBM."

Keren Primor Cohen, CEO of Ramot: "We hope that through this collaboration with Neovii, it will be possible to produce an effective vaccine that targets the coronavirus's Achilles' heel and will accelerate the development of a protective vaccine against this global threat."

Jrgen Pohle, Neovii CEO, commented, "The outbreak of the COVID-19 pandemic has demonstrated how fragile and vulnerable our societies are in the face of a pandemic. We are extremely excited about our collaboration with Professor Gershoni and TAU which provides Neovii with a first-in-class platform for the rapid development of promising vaccine candidates towards any future emerging pandemics including COVID-19. Furthermore, the COVID-19 vaccine is highly synergistic to Neovii's core expertise in the development and manufacturing of passive polyclonal antibodies and provides an opportunity to bring a COVID-19 immunotherapy in a rapid manner."

Neovii's long-standing and well-established experience and capabilities in developing, manufacturing and commercializing biopharmaceuticals will support the ambition to have a vaccine ready for use in broader population in an accelerated timeline.

About Neovii

Swiss-based Neovii, a member of Israeli-based Neopharm Group, is an independent, rapidly growing commercial-stage biopharmaceutical company with a patient-focused mission to develop and market novel, life-transforming therapies. Neovii has been dedicated for over three decades to improving the outcomes in transplantation medicine and the treatment options for hemato-oncological as well as immune disorders.

Media Relations Contacts:Rebeca Thomas, Senior Account Director, Jango Communications+44 (0)1344 860612beca@jangocom.com

Read this article:
NEOVII to Develop a Novel Vaccine for COVID-19 in an Exclusive Partnership With Tel Aviv University - WFMZ Allentown

Cell Biology

The Impact of SETD2 on Tumor Microenvironment in Clear Cell RCC – Targeted Oncology

May 12, 2020 medical

Scott Haake, MD

The SET domain-containing protein 2 (SETD2) is common in clear cell renal cell carcinoma (RCC), occurring in about 10% to 15% of patients, and is known to play a role in the tumor microenvironment. However, investigators lack literature on the biology of the SETD2 mutation and how it could play a role in tumor growth.

At the 2019 International Kidney Cancer Symposium (IKCS), a study analyzed novel SETD2-dependent changes to the cellular lysine methylation landscape in the kidney cancer setting. The hypothesis was that SETD2-mutant tumors will have an increased sensitivity to therapies that target protein translation. Investigators utilized an agnostic approach with a mass spectrometry-based technique to evaluate these changes.

Overall, investigators observed a decrease in protein translations, which may represent a new therapeutic vulnerability of these cells that can be exploited with targeted therapies.

The key takeaway is that tumor genomics matter, and they drive biology, said Scott Haake, MD, following his presentation at the 2019 IKCS. If we can exploit that biology to apply targeted therapies, this is an opportunity for new therapeutic maneuvers that are tailored to the patients and individual tumors.

In an interview with Targeted Oncology, Haake, professor of Medicine, Vanderbilt University School of Medicine, discussed the current understandings of SETD2 mutations in clear cell RCC and the findings presented at the 2019 IKCS.

TARGETED ONCOLOGY: What do we know thus far about how SETD2 influences the tumor microenvironment?

Haake:SETD2 is mutated in 10% to 15% of clear cell RCC. Its role in the tumor microenvironment specifically is probably less well understood. However, it is thought to be a critical driver of tumor growth and progression as loss of SETD2 function is thought to increase as tumors metastasize.

TARGETED ONCOLOGY: Could you explain the biology of SETD?

Haake: Its less well understood than we would like to acknowledge. Classically SETD2 modulates the epigenetics of the cell or chromatin structure, which is the way that the DNA is packaged into the cell, and when you lose SETD2, it changes that structure in a way that is thought to influence gene expression. This is classically how we think about SETD2 biology. More recently, there has been data showing that SETD2 has many other functions, including modulating tubulin structure which is important in mitosis and chromosome segregation, as well as inflammatory signaling through STAT1.

Because we still have an incomplete picture of how SETD2 is important for tumor development, this was 1 of the impotencies for the current study where we took an agnostic approach to see the different ways thatSETD2 can modulate cell function in the context of cancer.

[To identify SEDT2 mutations], stereotypical next-generation sequencing approaches are the way of the future, and that is what everyone does.

TARGETED ONCOLOGY:Are there any other therapies for targeting theSETD2mutation?

Haake: Through our work, we have identified a novel role of SETD2 regulating protein translation. I have mentioned the classic ways that SETD2 influences cell biology, but our work suggests that in addition, SETD2is regulating protein translation at the ribosome by regulating methylation of certain translation elongation factors. In SETD2-mutant tumors, you lose methylation of these elongation factors, which decreases protein translation, so we think this might be an opportunity for synthetic lethality in SETD2-mutant tumors where these cells will have increased sensitivity to therapies that target protein translation, or at least that is the hypothesis we are pursuing.

TARGETED ONCOLOGY:Could you provide an overview of your presentation on SETD2 from the 2019 IKCS?

Haake: There are a number of targets for SETD2 that have been described in the literature, but we wanted to take a more agnostic approach. We used a mass spectrometry-based technique to look at SETD2-dependent changes in lysine methylation in proximal renal tubular cells, which are the cells from which RCC is thought to derive.

One of the things we observed was the loss of methylation in a number of distinct lysine residues within an elongation factor called EF1A. It has been shown in lung cancer that loss of methylation of these lysine residues in EF1A correlates with decreased protein translation and decreased progression of tumors. Sure enough, when we look at this in our kidney cancer cells, we see decreased protein translation, and when we look at tumors from humans with SETD2 mutations, we also observed similar changes. We think this is a new aspect of SETD2 biology in the context of kidney cancer and may represent a therapeutic vulnerability of these cells, which we can exploit.

TARGETED ONCOLOGY:What are the next steps for this research?

Haake: That is really where we are at now. We are doing a handful of experiments to validate the mechanism I proposed, but we are also testing drugs and wild-type, as well as SETD2-knockout cells which target protein translation to test this hypothesis that SETD2-knockout cells are going to have increased sensitivity to these sorts of drugs.

TARGETED ONCOLOGY:What is the key takeaway from your presentation?

Haake: The key takeaway is that tumor genomics matter, and they drive biology. If we can exploit that biology to apply targeted therapies, this is an opportunity for new therapeutic maneuvers that are tailored to the patients and individual tumors.

Cell Biology

Why are there so few antivirals? | Cosmos – Cosmos

May 12, 2020 medical

By Christine Carson, University of Western Australia, and Rachel Roper, East Carolina University

As the end of the second world war neared, mass production of the newly developed antibiotic penicillin enabled life-saving treatment of bacterial infections in wounded soldiers. Since then, penicillin and many other antibiotics have successfully treated a wide variety of bacterial infections.

But antibiotics dont work against viruses; antivirals do. Since the outbreak of the coronavirus pandemic, researchers and drug companies have struggled to find an antiviral that can treat SARS-CoV-2, the virus that causes COVID-19.

Why are there so few antivirals? The answer boils down to biology, and specifically the fact viruses use our own cells to multiply. This makes it hard to kill viruses without killing our own cells in the process.

The differences between bacterial and human cells are what make antibiotics possible.

Bacteria are self-contained life forms that can live independently without a host organism. They are similar to our cells, but also have many features not found in humans.

For example, penicillin is effective because it interferes with the construction of the bacterial cell wall. Cell walls are made of a polymer called peptidoglycan. Human cells dont have a cell wall or any peptidoglycan. So antibiotics that prevent bacteria from making peptidoglycan can inhibit bacteria without harming the human taking the medicine. This principle is known as selective toxicity.

Unlike bacteria, viruses cannot replicate independently outside a host cell. There is a debate over whether they are really living organisms at all.

To replicate, viruses enter a host cell and hijack its machinery. Once inside, some viruses lie dormant, some replicate slowly and leak from cells over a prolonged period, and others make so many copies that the host cell bursts and dies. The newly replicated virus particles then disperse and infect new host cells.

An antiviral treatment that intervenes in the viral life cycle during these events could be successful. The problem is that if it targets a replication process that is also important to the host cell, it is likely to be toxic to the human host as well.

Killing viruses is easy. Keeping host cells alive while you do it is the hard part.

Successful antivirals target and disrupt a process or structure unique to the virus, thereby preventing viral replication while minimising harm to the patient. The more dependent the virus is on the host cell, the fewer targets there are to hit with an antiviral. Unfortunately, most viruses offer a few points of unique difference that can be targeted.

Another complication is that different viruses vary from each other much more than different bacteria do. Bacteria all have double-stranded DNA genomes and replicate independently by growing larger and then splitting into two, similar to human cells.

But there is extreme diversity between different viruses. Some have DNA genomes while others have RNA genomes, and some are single-stranded while others are double-stranded. This makes it practically impossible to create a broad spectrum antiviral drug that will work across different virus types.

Nevertheless, points of difference between humans and viruses do exist, and their exploitation has led to some success. One example is influenza A, which is one form of the flu.

Influenza A tricks human cells so it can enter them. Once inside our cells, the virus needs to undress, removing its outer coat to release its RNA into the cell.

A viral protein called matrix-2 protein is key to this process, facilitating a series of events that releases the viral RNA from the virus particle. Once the viral RNA is released inside the host cell, it is transported to the cell nucleus to start viral replication.

But if a drug jams the matrix-2 protein, the viral RNA cant exit the virus particle to get to the cell nucleus, where it needs to be to replicate. So, the infection stalls. Amantadine and rimantadine were early antiviral successes targeting the matrix-2 protein.

Zanamivir (Relenza) and oseltamivir (Tamiflu) are newer drugs that have also had success in treating patients infected with influenza A or B. They work by blocking a key viral enzyme, obstructing virus release from the cell, slowing the spread of infection within the body, and minimising the damage the infection causes.

A COVID-19 vaccine may be difficult to create. So testing antivirals to find one that can effectively treat COVID-19 remains an important goal.

Much depends on knowing the intricacies of the SARS-CoV-2 virus and its interactions with human cells. If researchers can identify unique elements in how it survives and replicates, we can exploit these points of weakness and make an effective antiviral treatment.

This article is supported by the Judith Neilson Institute for Journalism and Ideas.

Christine Carson, Senior Research Fellow, School of Biomedical Sciences, University of Western Australia and Rachel Roper, Associate Professor of Microbiology and Immunology, East Carolina University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Cell Biology

What needs to go right to get a coronavirus vaccine in 12-18 months – The Southern Maryland Chronicle

May 12, 2020 medical

By: Marcos E. Garca-Ojeda, Professor of Molecular and Cell Biology, University of California, Merced

I, like many Americans, miss the pre-pandemic world of hugging family and friends, going to work and having dinner at a restaurant. A protective vaccine for SARS-Cov2 is likely to bethe most effective public health toolto get back to that world.

Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, cautiously estimates that a vaccine could be available in12 to 18 months.

I am aprofessor of microbiology and immunologyand study how the immune system develops. I think Dr. Faucis estimate is an optimistic one, but possible.

Traditional vaccine development is a long and complicated process. Only about 6% of vaccine candidates are eventuallyapproved for public use, and the process takes10.7 years, on average.

But these are not traditional times. Researchers around the world areinnovating the process of vaccine developmentin real time to develop a vaccine as fast as possible. So how close are we to a vaccine?

Vaccines prevent disease by boosting a persons natural immune response against a microbe that they havenot encountered before. There are a number of different types of vaccines in development for SARS-CoV-2 and they fall into three broad categories:traditional killed-virus vaccines, protein-based vaccines and gene-based vaccines. No matter the type, every single vaccine candidate must go through the same vetting process before it can be put into use.

Once researchers have developed a potential candidate, they begin the first step of testing in laboratories, called preclinical studies. Scientists use laboratory animals to examine if the candidate vaccine induces an immune response to the virus and to check whether the vaccine causes any obvious medical problems.

Once a vaccine is proven safe in animals, researchers begin human testing. This is where thefederal Food and Drug Administrationbegins to regulate the process.

Phase 1 studies test for safety and proof-of-concept. Researchers give a small number of human volunteers the vaccine. Then they look for medical problems and see if it induces some sort of immune response.

In Phase 2 studies, researchers give the vaccine to hundreds of volunteers to determine the optimal vaccine composition, dose and vaccination schedule.

The final step before a vaccine is approved by the FDA for broad use is a Phase 3 trial. These involvethousands of volunteersand provide data on how good the vaccine is at preventing infection. These large trials will also uncover rarer side effects or health issues that may not show up in the smaller trials.

If in any of these phases a vaccine candidate appears to be ineffective or cause harm to people, the researchers must start over with a new candidate.

After a vaccine candidate successfully completes these clinical trials, a medical regulatory panel in the FDA looks at the evidence, and if the vaccine is effective and safe, approves it for general use. Experts estimate that the whole process costs betweenUS$1 billion and $5 billion.

But approval is not the only hurdle. As has been demonstrated by thesevere lack of coronavirus testing, easy and fast production of a test or vaccine is as critical as having one that works.

Both clinical efficacy and ease of production must be considered when asking how long until a vaccine is ready.

As of April 30, 2020, there were eight vaccine candidates currently in Phase 1 (or joint Phase 1/Phase 2) clinical trials and 94 vaccines candidatesin preclinical studies.

Three of the eight aretraditional vaccinesthat useinactivatedor killed virus. Two of the others areprotein-basedvaccines that use amodified cold virus to deliver the proteinthat will stimulate the immune response.

The final three vaccines in Phase 1 or 2 trials, and the only two in the U.S., are gene-based vaccines. To me, these seem like the most promising.

Gene-based vaccines contain a gene or part of a gene from the virus that causes COVID-19, but not the virus itself. When a person is injected with one of these vaccines, their own cells read the injected gene and make a protein that is a part of the coronavirus. This one protein isnt dangerous by itself, but it should trigger an immune response that would lead to immunity from the coronavirus.

Gene-based vaccinescome in DNA form, like the vaccinein Phase 1 clinical trialsfrom Inovio Pharmaceuticals in the U.S., or in RNA form, like the vaccine in a simultaneous Phase 1/Phase 2 trial from theGerman company BioNTechand the vaccine in Phase 1 trials from theU.S.-based Moderna.

No gene-based vaccines have ever been approved for human use, but DNA vaccines are used onanimals, and a few were inclinical trialsforthe Zika virus.

In the past, researchers have struggled to develop DNA vaccines that produce strong immune responses, but new techniqueslook promising. RNA vaccines tendto be more effectivein animal studies but have also required innovations before human use. It may be that the time ofgene-based vaccines has arrived.

Another benefit of gene-based vaccines is that manufacturers would likely be able to produce large amountsmuch faster than traditional vaccines. DNA and RNA vaccines would also bemore shelfstable than conventional vaccinessince they dont use ingredients like cell components or chicken eggs. This would make distribution, especially to rural areas, easier.

The three gene-based vaccines and the five other candidates face many challenges before you or I will be vaccinated. The fact that they are in Phase 1 and 2 trials is encouraging, but the very point of clinical trials is to reveal any problems with a vaccine candidate.

And there are alot of potential problems. The preclinical results in laboratory animals might not translate well to people. The level of immune protection might be low. And people may react adversely when injected with the vaccine.

Any coronavirus vaccine could also produce a dangerous reaction called immune enhancement, where the vaccine actually worsens the symptoms of a coronavirus infection. This is rare, buthas happened with past vaccine candidatesfor dengue fever and other viruses.

So, how long before we have a vaccine against the COVID-19 virus?

No vaccines have made it through Phase 1 or Phase 2 trials yet, and Phase 3 trials generally take between one and four years. If researchers get lucky and one of these first vaccines is both safe and effective, we are still at least a year away from knowing that. At that point manufacturers would need to start producing and distributing the vaccine at a massive scale.

It is unclear what percent of the population would need to be vaccinated against SARS-CoV-2, but in general, you need to immunize between 80% and 95% of the population to have effectiveherd immunity. Depending on what the virus does in the coming months, that might not be necessary, but if it is, thats 260-300 million people in the U.S. alone.

Researchers are doing everything they can to develop a vaccine as fast as possible while still making sure it is effective and safe. Manufacturers can help by preparing flexible systems that could be ready to produce whichever candidate gets across the finish line first.

If everything goes well, Faucis 12- to 18-month prediction may be right. If so, it will be thanks to the tireless work of scientists, the support of international organizations and manufacturers all innovating and working together to fight this virus.

Marcos E. Garca-Ojeda, Professor of Molecular and Cell Biology, University of California, Merced

This article is republished from The Conversation under a Creative Commons license. Read the original article.

The Southern Maryland Chronicle is a local, small business entrusted to provide factual, unbiased reporting to the Southern Maryland Community.While we look to local businesses for advertising, we hope to keep that cost as low as possible in order to attract even the smallest of local businesses and help them get out to the public. We must also be able to pay employees(part-time and full-time), along with equipment, and website related things. We never want to make the Chronicle a pay-wall style news site.

To that end, we are looking to the community to offer donations. Whether its a one-time donation or you set up a reoccurring monthly donation. It is all appreciated. All donations at this time will be going to furthering the Chronicle through hiring individuals that have the same goals of providing fair, and unbiased news to the community. For now, donations will be going to a business PayPal account I have set-up for the Southern Maryland Chronicle, KDC Designs. All business transactions currently occur within this PayPal account. If you have any questions regarding this you can email me at [emailprotected]

Thank you for all of your support and I hope to continue bringing Southern Maryland the best news possible for a very long time. David M. Higgins II

Go here to read the rest:
What needs to go right to get a coronavirus vaccine in 12-18 months - The Southern Maryland Chronicle

Cell Biology

Single Cell Sequencing: Transform Your Immunology and Cancer Research from Bulk to Single Cell Analysis, Upcoming Webinar Hosted by Xtalks – PR Web

May 12, 2020 medical

Xtalks Life Science Webinars

TORONTO (PRWEB) May 12, 2020

Single cell sequencing has transformed our ability to discern the cellular and molecular makeup of human immune systems and tissues in a unique manner with a level of precision that other omic technologies are unable to provide. Coupled with rigorous analysis, this technology is able to identify rare cell populations/subtypes and provide novel insights about pathways and thus transform our ability to characterize human disease, as well as, drug targeting through a deeper understanding of underlying biology.

Single cell RNA sequencing, in particular, allows a researcher to identify complex heterogeneous cell types at a molecular level. For infectious disease research, single cell data analysis helps us understand our immune system responses to different pathogens. In cancer studies, this means a deeper understanding of the ecosystems of malignant cells; providing better resolution of the tumor microenvironment. This ultimately helps to more efficiently and effectively treat diseases by different modalities such as cell-based and immuno-therapies.

In this webinar, please join our invited guest speakers as we discuss the advantages and challenges of single cell sequencing and how this technology has helped deliver a deeper understanding of disease and cellular biology in unique and complementary ways to other omics technologies.

Join Jeffrey Wallin, PhD, Sr. Director Biomarkers, Gilead Sciences, Rosha Poudyal, Science & Technology Advisor, 10X Genomics, Kristof O'Connor, Sales Executive, 10X Genomics and Hongye Sun, PhD, Scientific Fellow, WuXi NextCODE in a live webinar on Wednesday, May 27, 2020 at 10am EDT (3pm BST/UK).

For more information or to register for this event, visit Single Cell Sequencing: Transform Your Immunology and Cancer Research from Bulk to Single Cell Analysis.

ABOUT XTALKSXtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com.

For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar/.

Share article on social media or email:

Follow this link:
Single Cell Sequencing: Transform Your Immunology and Cancer Research from Bulk to Single Cell Analysis, Upcoming Webinar Hosted by Xtalks - PR Web

Cell Biology

Dyno Therapeutics Announces Presentations at 2020 American Society of Gene and Cell Therapy Conference – BioSpace

May 12, 2020 medical

Dyno sponsors ASGCT virtual career fair

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dyno Therapeutics, a biotechnology company applying artificial intelligence (AI) to gene therapy, today announced two presentations and a poster at the American Society of Gene and Cell Therapy (ASGCT) conference being held as a virtual meeting on May 12-15, 2020.

Details for the presentations and poster are as follows:

Presentations

Title: Artificial intelligence powered design of synthetic AAV capsids without pre-existing immunity for the universal treatment of all patientsPresenter: Eric Kelsic, Ph.D., Chief Executive Officer and Co-founder, Dyno TherapeuticsEducation Session Title: Synthetic Biology Meets Immunology: DNA and RNA ToolsDate and Time: Tuesday May 12, 2020; 2:40 - 3:15 p.m.

Title: Massively Parallel Deep Diversification of AAV Capsid Proteins by Machine LearningPresenter: Sam Sinai, Ph.D., Lead Machine Learning Scientist and Co-founder, Dyno TherapeuticsDate and Time: Wednesday May 13, 2020; 4:30 - 4:45 p.m.Oral Abstract Session Title: Vector and Cell Engineering, Production or Manufacturing IIIAbstract Number: 541

Poster

Title: Accurately Quantifying Transduction within Barcoded AAV Capsid Libraries via Tracking of Single-Molecule ID TagsPresenters: Kathy Lin, Ph.D., Computational Biology Scientist, and Jeff Gerold, Ph.D., Head of Data Science, Dyno TherapeuticsDate and Time: Thursday, May 14, 2020; 5:30 - 6:30 p.m.Poster Session Title: AAV Vectors - Virology and VectorologyAbstract Number: 1006

This poster will be available under the Publications section of the Dyno Therapeutics website at the time of the presentation at http://www.dynotx.com.

ASGCT Virtual Career Fair

Also at ASGCT 2020, Dyno is the main sponsor of the virtual career fair. Dyno is actively recruiting as the company continues to grow its current team of 20 employees and expects to double in the next year. Current listings can be found at the ASGCT Career Fair website and at http://www.dynotx.com.

About CapsidMap for Designing AAV Gene Therapies

By designing capsids that confer improved functional properties to Adeno-Associated Virus (AAV) vectors, Dynos proprietary CapsidMap platform overcomes the limitations of todays gene therapies on the market and in development. Todays treatments are primarily confined to a small number of naturally occurring AAV vectors that are limited by delivery, immunity, packaging size, and manufacturing challenges. CapsidMap uses artificial intelligence (AI) technology for the design of novel capsids, the cell-targeting protein shell of viral vectors. The CapsidMap platform applies leading-edge DNA library synthesis and next generation DNA sequencing to measure in vivo gene delivery properties in high throughput. At the core of CapsidMap are advanced search algorithms leveraging machine learning and Dynos massive quantities of experimental data, that together build a comprehensive map of sequence space and thereby accelerate the discovery and optimization of synthetic AAV capsids.

Dynos technology platform builds on certain intellectual property developed in the lab of George Church, Ph.D., who is Robert Winthrop Professor of Genetics at Harvard Medical School (HMS), a Core Faculty member at Harvards Wyss Institute for Biologically Inspired Engineering, and a co-founder of Dyno. Several of the technical breakthroughs that enabled Dynos approach to optimize synthetic AAV capsid engineering were described in a November 2019 publication in the journal Science, based on work conducted by Dyno founders and members of the Church Lab at HMS and the Wyss Institute. Dyno has an exclusive option to enter into a license agreement with Harvard University for this technology.

About Dyno Therapeutics

Dyno Therapeutics is a pioneer in applying artificial intelligence (AI) and quantitative high-throughput in vivo experimentation to gene therapy. The companys proprietary CapsidMap platform is designed to rapidly discover and systematically optimize superior Adeno-Associated Virus (AAV) capsid vectors with delivery properties that significantly improve upon current approaches to gene therapy and expand the range of diseases treatable with gene therapies. Dyno was founded in 2018 by experienced biotech entrepreneurs and leading scientists in the fields of gene therapy and machine learning. The company is located in Cambridge, Massachusetts. Visit http://www.dynotx.com for additional information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005459/en/

Biochemistry

The American Society for Biochemistry and Molecular Biology and Elsevier Announce New Publishing Partnership – P&T Community

May 12, 2020 medical

Collaboration paves the way for highly cited titles in biochemistry and molecular biology to transition to gold open access

NEW YORK, May 12, 2020 /PRNewswire/ -- The American Society for Biochemistry and Molecular Biology (ASBMB)andElsevier, a global information analytics business specializing in science and health, are delighted to announce a new partnership to publish the ASBMB's Journal of Biological Chemistry (JBC), Molecular & Cellular Proteomics (MCP) and Journal of Lipid Research (JLR). As part of this agreement, all three titles will move to a gold open access (OA) publishing model, making articles immediately and permanently available for everyone to read, download, copy and distribute. The journals will be hosted on Elsevier's leading online platform, ScienceDirect, beginning January 1, 2021.

The ASBMBadvances the mechanistic understanding of nature through promotion of the highest-quality research in biochemistry and molecular biology. The society's decision to partner with Elsevier to transition its journals from a hybrid subscription model to gold OA is a reflection of its commitment to make the high-quality papers that the journals publish immediately and permanently available to the public.

"ASBMB journals have earned a strong reputation for publishing papers based on the quality of the science and their contributions to advancing a field. The practicing scientists who lead and review for our journals will continue to make all editorial decisions," says ASBMB President Gerald Hart, Professor and Georgia Research Alliance Eminent Scholar at the University of Georgia. "Authors can count on ASBMB journals to continue providing rigorous, fast and fair peer review."

Elsevier's experience transitioning journals to gold open access was a key factor in their selection.

"We believe open science can bring meaningful benefits to society by enhancing research performance, so we are delighted to partner with the ASBMB to transition these highly-cited journals to gold open access. By working together, we can achieve a more inclusive, collaborative and transparent world of research," saidElsevier CEO KumsalBayazit.

Founded in 1906, the ASBMB has a long, rich history of supporting researchers throughout their careers. "I happen to be one of those scientists who benefited directly from ASBMB's educational resources at conferences early in my career," said Hlne Hodak, Publisher at Elsevier. "The ASBMB invested in generations of scientists over the years, and now they are part of academia, healthcare and various industries, including publishing. It is a thrill to be able to support the society in this transition and, in the process, support future generations of scientists."

"This partnership is going to benefit authors in several ways. It will streamline the submission process, make authors' research discoverable on the ScienceDirect platform, in addition to our own journals' websites, and, importantly, lower the cost of open-access publishing in ASBMB journals for both members and non-members," said Nancy Rodnan, Senior Director of Publications for the society.

About ASBMB

The American Society for Biochemistry and Molecular Biology is an international non-profit scientific and educational organization. With more than 11,000 members, made up of students, researchers, educators and industry professionals, the ASBMB is one of the largest molecular life science societies in the world.

Founded in 1906, the ASBMB's mission is to advance the science of biochemistry and molecular biology and to promote the understanding of the molecular nature of life processes. The society serves the scientific community through:

About Elsevier and society partnerships

Elsevier has long partnership records with over 600 learned scientific societies and works with organizations worldwide to support them in their mission of education support of the scientific communities. This includes support for global open science such as the partnership with Next Einstein Forum to launch the pan-African open access journal Scientific African. http://www.elsevier.com/books-and-journals/societies.

About Elsevier

Elsevieris a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we're committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. http://www.elsevier.com

Logo - https://mma.prnewswire.com/media/754760/Elsevier_Logo.jpg

Go here to read the rest:
The American Society for Biochemistry and Molecular Biology and Elsevier Announce New Publishing Partnership - P&T Community

Biochemistry

Automatic Veterinary Biochemistry Analyzer Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 – Cole of Duty

May 12, 2020 medical

URIT Medical Electronic

Moreover, the Automatic Veterinary Biochemistry Analyzer report offers a detailed analysis of the competitive landscape in terms of regions and the major service providers are also highlighted along with attributes of the market overview, business strategies, financials, developments pertaining as well as the product portfolio of the Automatic Veterinary Biochemistry Analyzer market. Likewise, this report comprises significant data about market segmentation on the basis of type, application, and regional landscape. The Automatic Veterinary Biochemistry Analyzer market report also provides a brief analysis of the market opportunities and challenges faced by the leading service provides. This report is specially designed to know accurate market insights and market status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=148824&utm_source=NYH&utm_medium=888

Table of Content

1 Introduction of Automatic Veterinary Biochemistry Analyzer Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Automatic Veterinary Biochemistry Analyzer Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Automatic Veterinary Biochemistry Analyzer Market, By Deployment Model

5.1 Overview

6 Automatic Veterinary Biochemistry Analyzer Market, By Solution

6.1 Overview

7 Automatic Veterinary Biochemistry Analyzer Market, By Vertical

7.1 Overview

8 Automatic Veterinary Biochemistry Analyzer Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Automatic Veterinary Biochemistry Analyzer Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=148824&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Automatic Veterinary Biochemistry Analyzer Market Size, Automatic Veterinary Biochemistry Analyzer Market Trends, Automatic Veterinary Biochemistry Analyzer Market Growth, Automatic Veterinary Biochemistry Analyzer Market Forecast, Automatic Veterinary Biochemistry Analyzer Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Our Trending Reports

Bone Cement Delivery System Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Plastic Compounding Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Biochemistry

Nutrients that help with immune system health and what they do – WWLTV.com

May 12, 2020 medical

In January of 2020, A Review of Micronutrients and the Immune System Working in Harmony to Reduce the Risk of Infection, was published in the online, peer review journal Nutrients. How prophetic that such a review would turn out to be critical three months later, with the worldwide onset of the pandemic Covid-19.

Researchers from the Linus Pauling Institute, Department of Biochemistry and Biophysics, Oregon State University and Bayer Consumer Care AG in Switzerland, comment in the Review that, immune support by micronutrients is historically based on vitamin C deficiency and supplementation in scurvy in early times.

Scurvy, a disease caused by vitamin C deficiency, causes swollen, bleeding gums, opening of previously healed wounds, weakness, feeling tired, with sore arms and legs- along with decreased red blood cells, changes to hair, and bleeding from the skin may also occur.

In 1753, researcher James Lind used three different diet approaches with men suffering from scurvy to determine that citrus fruits higher in vitamin C- provided a solution to this condition.

RELATED: Omega-3s reduce risk of neuroinflammation with aging | Maximum Wellness

RELATED: Mackie: Zinc a key player in immune system strength

RELATED: The more you walk, the lower your mortality risk | Maximum Wellness

RELATED: Vitamins that support lung function

In addition to vitamin C, vitamins A, D, E, B6, B12, and folate, along with minerals zinc, iron, copper, selenium, and magnesium also play vital, synergistic roles at every stage of the immune response.

Our immune defense system is composed of elaborate components, which provide physical and biochemical barriers, specialized immune cells, and antibodies that challenge and attack an invading pathogen.

The first line of defense is called the innate immune response characterized by a challenge by the skin, hair, and mucus membranes to provide a barrier into the body. In other words, limit access points of entry.

From there, its the job of biochemical attackers leukocytes such as neutrophils, natural killer (NK) cells, and macrophages - to identify non-self molecules to open fire and destroy the invader, which is marked as an antigen. Cytokines (involved in cell signaling), then repair any damage.

Thats followed by a second wave of attackers, T & B cells, which is the phase of the immune response characterized as adaptive immunity that remembers the invader and coordinates a joint response.

The researchers from Oregon State and Bayer AG provide an excellent overview, of the known mechanisms of micronutrients that are fundamental to immune function, and how inadequate intake might affect risk to infection. Here are few of the impacts of specific immune modulating nutrients.

Vitamin A - important for intestinal immune response, thus supporting the gut barrier; carotenoids (either provitamin A or non-provitamin A) have immunoregulatory actions.

Vitamin D calcitriol (a form of vitamin D3) regulates antimicrobial proteins responsible for modifying intestinal microbiota to a healthier composition and supporting the gut barrier, as well as, protecting the lungs against infection.

Vitamin C - promotes collagen synthesis and protects cell membranes from damage caused by free radicals, thus supporting integrity of epithelial barriers.

Vitamin E - protects cell membranes from damage caused by free radicals and support the integrity of epithelial barriers.

Vitamins B6, B12, Folate - involved in intestinal immune regulation (e.g., by mediating lymphocyte migration into the intestine) in the case of vitamin B6, while folate is essential for the survival of regulatory T cells in the small intestine. Human gut microbes use vitamin B12, as a cofactor for metabolic pathways, thus supporting the gut barrier. Folate is also important for sufficient antibody response to antigens.

Iron - essential for differentiation and growth of epithelial tissue.

Zinc - helps maintain integrity of skin and mucosal membrane (e.g., cofactor for metalloenzymes required for cell membrane repair); important in maintaining immune tolerance (i.e., the ability to recognize self from non-self).

Copper - role in functions of macrophages, neutrophils, and monocytes; enhances NK cell activity.

Selenium - helps to maintain antibody levels

Magnesium - cofactor of enzymes of nucleic acid metabolism and stabilizes structure of nucleic acids; involved in DNA replication and repair; roles in antigen binding to macrophages; regulates leukocyte activation; involved in the regulation of apoptosis (programed cell death).

Please keep in mind that each nutrient listed has additional immune support benefits, which are beyond the scope of this column. Nor are nutrient requirements listed, since that must depend on guidance from your physician.

What you can see, is the need to have a healthy eating plan and the support of a good multi-vitamin/mineral formula, as main components of your immune support plan adding various forms of daily exercise to round out the mix.

Sign up for Mackie Mail, on mackieshilstone.com - my free, weekly wellness update with Fitness in Small Spaces 90-second videos Monday, my Maximum Wellness podcast and script on Wednesday, and, on Friday you receive my WWL/WUPL 3-minute Workout Wednesday segment. You can also contact spencer@mackienutrition.com should you desire nutrition product shipped or locally delivered to your door. My 4 locally operated GNC franchise stores are open, regularly sanitized with appropriate staff and customer safety in place. Check mackieshilstone.com for store locations and hours.

More here:
Nutrients that help with immune system health and what they do - WWLTV.com

Biochemistry

Chitin Fertilizer Market Recent Trends and Developments, Challenges and Opportunities, key drivers and Restraints over the Forecast Period…

May 12, 2020 medical

Latest Report On Chitin Fertilizer Market including Market Landscape, and Market size, Revenues by players, Revenues by regions, Average prices, Competitive landscape, market Dynamics and industry trends and developments during the forecast period.

The global Chitin Fertilizer market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Chitin Fertilizer market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global market. The authors of the report profile leading companies of the global Chitin Fertilizer market, Also the details about important activities of leading players in the competitive landscape.

Key companies operating in the global Chitin Fertilizer market include: , Advanced Biopolymers, Heppe Medical Chitosan GmbH, G.T.C. UNION, Primex, Kitozyme, Novamatrix, Agratech International, Golden-Shell Pharmaceutical, Qingdao Yunzhou Biochemistry, Panvo Organics

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1741584/impact-of-covid-19-outbreak-on-chitin-fertilizer-global-and-united-states-market

The report predicts the size of the global Chitin Fertilizer market in terms of value and volume for the forecast period 2020-2026. As per the analysis provided in the report, the global Chitin Fertilizer market is expected to rise at a CAGR of xx % between 2020 and 2026 to reach a valuation of US$ xx million/billion by the end of 2026. In 2020, the global Chitin Fertilizer market attained a valuation of US$ XX million/billion. The market researchers deeply analyze the global Chitin Fertilizer industry landscape and the future prospects it is anticipated to create

Segmental Analysis

The report has classified the global Chitin Fertilizer industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Chitin Fertilizer manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Chitin Fertilizer industry.

Global Chitin Fertilizer Market Segment By Type:

, Shrimp, Crab, Krill, Lobsters, Insects, Squid, Others

Global Chitin Fertilizer Market Segment By Application:

Food & Beverages, Water Treatment, Agrochemicals, Personal Care, Biomedicine, Industrial, Pharmaceuticals, Others

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Chitin Fertilizer industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key questions answered in the report:

Get Full Report in your inbox within 24 hours at USD(3900):

https://www.qyresearch.com/settlement/pre/32a2c8dec6f283d4dbf76d9decd998e5,0,1,impact-of-covid-19-outbreak-on-chitin-fertilizer-global-and-united-states-market

Table of Content

1 Study Coverage1.1 Chitin Fertilizer Product Introduction1.2 Market Segments1.3 Key Chitin Fertilizer Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Chitin Fertilizer Market Size Growth Rate by Type1.4.2 Shrimp1.4.3 Crab1.4.4 Krill1.4.5 Lobsters1.4.6 Insects1.4.7 Squid1.4.8 Others1.5 Market by Application1.5.1 Global Chitin Fertilizer Market Size Growth Rate by Application1.5.2 Food & Beverages1.5.3 Water Treatment1.5.4 Agrochemicals1.5.5 Personal Care1.5.6 Biomedicine1.5.7 Industrial1.5.8 Pharmaceuticals1.5.9 Others1.6 Coronavirus Disease 2019 (Covid-19): Chitin Fertilizer Industry Impact1.6.1 How the Covid-19 is Affecting the Chitin Fertilizer Industry1.6.1.1 Chitin Fertilizer Business Impact Assessment Covid-191.6.1.2 Supply Chain Challenges1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Chitin Fertilizer Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-191.6.3.1 Government Measures to Combat Covid-19 Impact1.6.3.2 Proposal for Chitin Fertilizer Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Executive Summary2.1 Global Chitin Fertilizer Market Size Estimates and Forecasts2.1.1 Global Chitin Fertilizer Revenue 2015-20262.1.2 Global Chitin Fertilizer Sales 2015-20262.2 Chitin Fertilizer Market Size by Region: 2020 Versus 20262.3 Chitin Fertilizer Historical Market Size by Region (2021-2026)2.3.1 Global Chitin Fertilizer Retrospective Market Scenario in Sales by Region: 2015-20202.3.2 Global Chitin Fertilizer Retrospective Market Scenario in Revenue by Region: 2015-20202.4 Chitin Fertilizer Market Estimates and Projections by Region (2021-2026)2.4.1 Global Chitin Fertilizer Sales Forecast by Region (2021-2026)2.4.2 Global Chitin Fertilizer Revenue Forecast by Region (2021-2026) 3 Global Chitin Fertilizer Competitor Landscape by Players3.1 Global Top Chitin Fertilizer Sales by Manufacturers3.1.1 Global Chitin Fertilizer Sales by Manufacturers (2015-2020)3.1.2 Global Chitin Fertilizer Sales Market Share by Manufacturers (2015-2020)3.2 Global Chitin Fertilizer Manufacturers by Revenue3.2.1 Global Chitin Fertilizer Revenue by Manufacturers (2015-2020)3.2.2 Global Chitin Fertilizer Revenue Share by Manufacturers (2015-2020)3.2.3 Global Chitin Fertilizer Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Chitin Fertilizer Revenue in 20193.2.5 Global Chitin Fertilizer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Global Chitin Fertilizer Price by Manufacturers3.4 Global Chitin Fertilizer Manufacturing Base Distribution, Product Types3.4.1 Chitin Fertilizer Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Chitin Fertilizer Product Type3.4.3 Date of International Manufacturers Enter into Chitin Fertilizer Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Chitin Fertilizer Market Size by Type (2015-2020)4.1.1 Global Chitin Fertilizer Sales by Type (2015-2020)4.1.2 Global Chitin Fertilizer Revenue by Type (2015-2020)4.1.3 Chitin Fertilizer Average Selling Price (ASP) by Type (2015-2026)4.2 Global Chitin Fertilizer Market Size Forecast by Type (2021-2026)4.2.1 Global Chitin Fertilizer Sales Forecast by Type (2021-2026)4.2.2 Global Chitin Fertilizer Revenue Forecast by Type (2021-2026)4.2.3 Chitin Fertilizer Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Chitin Fertilizer Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026)5.1 Global Chitin Fertilizer Market Size by Application (2015-2020)5.1.1 Global Chitin Fertilizer Sales by Application (2015-2020)5.1.2 Global Chitin Fertilizer Revenue by Application (2015-2020)5.1.3 Chitin Fertilizer Price by Application (2015-2020)5.2 Chitin Fertilizer Market Size Forecast by Application (2021-2026)5.2.1 Global Chitin Fertilizer Sales Forecast by Application (2021-2026)5.2.2 Global Chitin Fertilizer Revenue Forecast by Application (2021-2026)5.2.3 Global Chitin Fertilizer Price Forecast by Application (2021-2026) 6 China by Players, Type and Application6.1 China Chitin Fertilizer Market Size YoY Growth 2015-20266.1.1 China Chitin Fertilizer Sales YoY Growth 2015-20266.1.2 China Chitin Fertilizer Revenue YoY Growth 2015-20266.1.3 China Chitin Fertilizer Market Share in Global Market 2015-20266.2 China Chitin Fertilizer Market Size by Players (International and Local Players)6.2.1 China Top Chitin Fertilizer Players by Sales (2015-2020)6.2.2 China Top Chitin Fertilizer Players by Revenue (2015-2020)6.3 China Chitin Fertilizer Historic Market Review by Type (2015-2020)6.3.1 China Chitin Fertilizer Sales Market Share by Type (2015-2020)6.3.2 China Chitin Fertilizer Revenue Market Share by Type (2015-2020)6.3.3 China Chitin Fertilizer Price by Type (2015-2020)6.4 China Chitin Fertilizer Market Estimates and Forecasts by Type (2021-2026)6.4.1 China Chitin Fertilizer Sales Forecast by Type (2021-2026)6.4.2 China Chitin Fertilizer Revenue Forecast by Type (2021-2026)6.4.3 China Chitin Fertilizer Price Forecast by Type (2021-2026)6.5 China Chitin Fertilizer Historic Market Review by Application (2015-2020)6.5.1 China Chitin Fertilizer Sales Market Share by Application (2015-2020)6.5.2 China Chitin Fertilizer Revenue Market Share by Application (2015-2020)6.5.3 China Chitin Fertilizer Price by Application (2015-2020)6.6 China Chitin Fertilizer Market Estimates and Forecasts by Application (2021-2026)6.6.1 China Chitin Fertilizer Sales Forecast by Application (2021-2026)6.6.2 China Chitin Fertilizer Revenue Forecast by Application (2021-2026)6.6.3 China Chitin Fertilizer Price Forecast by Application (2021-2026) 7 North America7.1 North America Chitin Fertilizer Market Size YoY Growth 2015-20267.2 North America Chitin Fertilizer Market Facts & Figures by Country7.2.1 North America Chitin Fertilizer Sales by Country (2015-2020)7.2.2 North America Chitin Fertilizer Revenue by Country (2015-2020)7.2.3 U.S.7.2.4 Canada 8 Europe8.1 Europe Chitin Fertilizer Market Size YoY Growth 2015-20268.2 Europe Chitin Fertilizer Market Facts & Figures by Country8.2.1 Europe Chitin Fertilizer Sales by Country8.2.2 Europe Chitin Fertilizer Revenue by Country8.2.3 Germany8.2.4 France8.2.5 U.K.8.2.6 Italy8.2.7 Russia 9 Asia Pacific9.1 Asia Pacific Chitin Fertilizer Market Size YoY Growth 2015-20269.2 Asia Pacific Chitin Fertilizer Market Facts & Figures by Country9.2.1 Asia Pacific Chitin Fertilizer Sales by Region (2015-2020)9.2.2 Asia Pacific Chitin Fertilizer Revenue by Region9.2.3 China9.2.4 Japan9.2.5 South Korea9.2.6 India9.2.7 Australia9.2.8 Taiwan9.2.9 Indonesia9.2.10 Thailand9.2.11 Malaysia9.2.12 Philippines9.2.13 Vietnam 10 Latin America10.1 Latin America Chitin Fertilizer Market Size YoY Growth 2015-202610.2 Latin America Chitin Fertilizer Market Facts & Figures by Country10.2.1 Latin America Chitin Fertilizer Sales by Country10.2.2 Latin America Chitin Fertilizer Revenue by Country10.2.3 Mexico10.2.4 Brazil10.2.5 Argentina 11 Middle East and Africa11.1 Middle East and Africa Chitin Fertilizer Market Size YoY Growth 2015-202611.2 Middle East and Africa Chitin Fertilizer Market Facts & Figures by Country11.2.1 Middle East and Africa Chitin Fertilizer Sales by Country11.2.2 Middle East and Africa Chitin Fertilizer Revenue by Country11.2.3 Turkey11.2.4 Saudi Arabia11.2.5 U.A.E 12 Company Profiles12.1 Advanced Biopolymers12.1.1 Advanced Biopolymers Corporation Information12.1.2 Advanced Biopolymers Description, Business Overview and Total Revenue12.1.3 Advanced Biopolymers Sales, Revenue and Gross Margin (2015-2020)12.1.4 Advanced Biopolymers Chitin Fertilizer Products Offered12.1.5 Advanced Biopolymers Recent Development12.2 Heppe Medical Chitosan GmbH12.2.1 Heppe Medical Chitosan GmbH Corporation Information12.2.2 Heppe Medical Chitosan GmbH Description, Business Overview and Total Revenue12.2.3 Heppe Medical Chitosan GmbH Sales, Revenue and Gross Margin (2015-2020)12.2.4 Heppe Medical Chitosan GmbH Chitin Fertilizer Products Offered12.2.5 Heppe Medical Chitosan GmbH Recent Development12.3 G.T.C. UNION12.3.1 G.T.C. UNION Corporation Information12.3.2 G.T.C. UNION Description, Business Overview and Total Revenue12.3.3 G.T.C. UNION Sales, Revenue and Gross Margin (2015-2020)12.3.4 G.T.C. UNION Chitin Fertilizer Products Offered12.3.5 G.T.C. UNION Recent Development12.4 Primex12.4.1 Primex Corporation Information12.4.2 Primex Description, Business Overview and Total Revenue12.4.3 Primex Sales, Revenue and Gross Margin (2015-2020)12.4.4 Primex Chitin Fertilizer Products Offered12.4.5 Primex Recent Development12.5 Kitozyme12.5.1 Kitozyme Corporation Information12.5.2 Kitozyme Description, Business Overview and Total Revenue12.5.3 Kitozyme Sales, Revenue and Gross Margin (2015-2020)12.5.4 Kitozyme Chitin Fertilizer Products Offered12.5.5 Kitozyme Recent Development12.6 Novamatrix12.6.1 Novamatrix Corporation Information12.6.2 Novamatrix Description, Business Overview and Total Revenue12.6.3 Novamatrix Sales, Revenue and Gross Margin (2015-2020)12.6.4 Novamatrix Chitin Fertilizer Products Offered12.6.5 Novamatrix Recent Development12.7 Agratech International12.7.1 Agratech International Corporation Information12.7.2 Agratech International Description, Business Overview and Total Revenue12.7.3 Agratech International Sales, Revenue and Gross Margin (2015-2020)12.7.4 Agratech International Chitin Fertilizer Products Offered12.7.5 Agratech International Recent Development12.8 Golden-Shell Pharmaceutical12.8.1 Golden-Shell Pharmaceutical Corporation Information12.8.2 Golden-Shell Pharmaceutical Description, Business Overview and Total Revenue12.8.3 Golden-Shell Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)12.8.4 Golden-Shell Pharmaceutical Chitin Fertilizer Products Offered12.8.5 Golden-Shell Pharmaceutical Recent Development12.9 Qingdao Yunzhou Biochemistry12.9.1 Qingdao Yunzhou Biochemistry Corporation Information12.9.2 Qingdao Yunzhou Biochemistry Description, Business Overview and Total Revenue12.9.3 Qingdao Yunzhou Biochemistry Sales, Revenue and Gross Margin (2015-2020)12.9.4 Qingdao Yunzhou Biochemistry Chitin Fertilizer Products Offered12.9.5 Qingdao Yunzhou Biochemistry Recent Development12.10 Panvo Organics12.10.1 Panvo Organics Corporation Information12.10.2 Panvo Organics Description, Business Overview and Total Revenue12.10.3 Panvo Organics Sales, Revenue and Gross Margin (2015-2020)12.10.4 Panvo Organics Chitin Fertilizer Products Offered12.10.5 Panvo Organics Recent Development12.11 Advanced Biopolymers12.11.1 Advanced Biopolymers Corporation Information12.11.2 Advanced Biopolymers Description, Business Overview and Total Revenue12.11.3 Advanced Biopolymers Sales, Revenue and Gross Margin (2015-2020)12.11.4 Advanced Biopolymers Chitin Fertilizer Products Offered12.11.5 Advanced Biopolymers Recent Development 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Chitin Fertilizer Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Chitin Fertilizer Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details

About Us

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the rest here:
Chitin Fertilizer Market Recent Trends and Developments, Challenges and Opportunities, key drivers and Restraints over the Forecast Period...